Medexus Pharmaceuticals (TSX:MDP) Other Long-Term Liabilities: C$0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:MDP Medexus Pharmaceuticals Inc TSX:MDP
53 GF Score
Price C$5.37
GF Value C$2.04
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals Other Long-Term Liabilities?

Medexus Pharmaceuticals TSX:MDP +1.32% 53 Other Long-Term Liabilities is C$0.0 Mil as of Jun. 2026. GuruFocus rates TSX:MDP with a GF Score™ of 53/100 and a GF Value™ of C$2.04 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Medexus Pharmaceuticals's other long-term liabilities for the quarter that ended in Jun. 2026 was C$0.0 Mil.

Medexus Pharmaceuticals's quarterly other long-term liabilities declined from Dec. 2025 (C$0.0 Mil) to Mar. 2026 (C$-0.0 Mil) but then increased from Mar. 2026 (C$-0.0 Mil) to Jun. 2026 (C$0.0 Mil).

Medexus Pharmaceuticals's annual other long-term liabilities increased from Mar. 2024 (C$-0.0 Mil) to Mar. 2025 (C$-0.0 Mil) but then declined from Mar. 2025 (C$-0.0 Mil) to Mar. 2026 (C$-0.0 Mil).

Medexus Pharmaceuticals Other Long-Term Liabilities Related Terms

Medexus Pharmaceuticals Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals Other Long-Term Liabilities Chart

Medexus Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.43 0.00 -0.00 -0.00 -0.00

Medexus Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00
TSX:MDP
53GF Score
Medexus Pharmaceuticals Inc TSX:MDP
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medexus Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of C$0.0 Mil mean?
Medexus Pharmaceuticals (TSX:MDP) has a Other Long-Term Liabilities of C$0.0 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Medexus Pharmaceuticals and its competitors.
Is Medexus Pharmaceuticals' Other Long-Term Liabilities too high?
Medexus Pharmaceuticals' current Other Long-Term Liabilities is C$0.0 Mil. Overall, Medexus Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Other Long-Term Liabilities compare to ZTS?
Medexus Pharmaceuticals' Other Long-Term Liabilities of C$0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Medexus Pharmaceuticals and its competitors. Medexus Pharmaceuticals's current Other Long-Term Liabilities is C$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$2.04, compared to a current price of C$5.37 — trading 163.2% above its estimated fair value. The current Other Long-Term Liabilities is C$0.0 Mil. Medexus Pharmaceuticals' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current Other Long-Term Liabilities is C$0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of C$5.37 is trading 163.2% above its estimated GF Value™ of C$2.04. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for TSX:MDP:

  • Other Long-Term Liabilities: C$0.0 Mil
  • GF Value™: C$2.04 vs. price of C$5.37 (163.2% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medexus Pharmaceuticals Business Description

Other Exchanges MEDXF:USAP731:Germany
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
53GF Score

Get the complete analysis for TSX:MDP

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$5.37
Price
C$2.04
GF Value